QBT1 task 5 Final paper Dec 20 2012
QBT1 task 5 Final paper Dec 20 2012
Possibly the most imperative public health challenge for the United States today is the obesity epidemic the population has. This obesity epidemic, is linked to an array of costly and debilitating health consequences. The widespread challenge of obesity and the health problems and concerns that go with that is an American public health problem. FDA’s approval of two new medications that can help to decrease some of the obesity , decrease some of the chronic diseases associated with obesity, and decrease the costs associated with obesity. This essay will be addressing these pertinent problems and will prove that the new FDA drugs approved for weight loss will help American’s with weight loss that will decrease obesity, decrease chronic illnesses that are associated with obesity and decrease health care costs. Prevention of obesity along with investing in research is necessary for us to see a change in the obesity epidemic (Hammond, 2012). Research suggests that decreasing obesity will decrease the costs of health care, decrease chronic illnesses associated with obesity. Total obesity costs would be much more reduced, along with the cost for other conditions caused by excess weight in our population (Finkelstein, Trogdon, Cohen & Dietz, 2009). Research suggests that the newest FDA approved diet pills will benefit Americans by decreasing obesity, decreasing chronic diseases associated with obesity and decreasing health care costs.
Research shows that newest FDA approved diet pills Qysimia, and Blviq (lorcaserin), are helping to decrease obesity in the American population that were taking these medications. The new diet drugs approved by FDA will benefit Americans by decreasing obesity rates in the American population. With two-thirds of all our population being obese or overweight or and the related cost of health costs, FDA was under pressure to approve any weight loss treatments (Berkrot & Yukhananov, 2012). The Food and Drug Administration (FDA) permitted long-term weight loss obesity drugs for the first time in 13 years, these drugs are suppose to help unhealthy overweight and obese Americans with weight control that have been unsuccessful (FDA, 2012). These two new drugs, Belviq (lorcaserin) and Qsymia will be a tool to help Americans get and stay at a healthy weight (FDA, 2012).
Belviq (lorcaserin) is one of the two new drugs that have been approved by the FDA. Resesearch currently showing promise and benefit from this medication. Belviq (lorcaserin) which drug’s efficacy submitted by FDA and Arena pharmaceuticals show a weight loss of five percent of their starting weight, averaging twelve pounds (Park, 2012a). Belviq (lorcaserin) works activating the brain receptors for serotonin which help to control appetite. Arena researchers explain that their drug is designed to seek out these appetite serotonin receptors and saturate them so that appetite is controlled. FDA and Arena pharmaceuticals show a weight loss of five percent of their starting weight, averaging twelve pounds. The best results have been shown in people that are on a healthy diet and an exercise program (Park, 2012a). FDA has approved this medications for obese patients with a BMI of 30 or above, or if a BMI of 27 and high cholesterol, hypertension or Type 2 diabetes. Side effects associated with this medication are fatigue, dizziness, dry mouth, constipation, headache and nausea; side effects for diabetic patients are fatigue, low blood sugar, headache, back pain and cough. The standard labeling for Belviq suggests that the drug be terminated in patients who fail to drop 5 percent of their body weight after 12 weeks of therapy, because they will probably not start achieving weight loss. When Belviq is given 10 milligrams twice a day, Belviq does not appear to activate the serotonin 2B receptor, which is what caused the withdrawal...
Please join StudyMode to read the full document